Search

Your search keyword '"mRNA‐1273 vaccine"' showing total 23 results

Search Constraints

Start Over You searched for: Descriptor "mRNA‐1273 vaccine" Remove constraint Descriptor: "mRNA‐1273 vaccine" Database OpenAIRE Remove constraint Database: OpenAIRE
23 results on '"mRNA‐1273 vaccine"'

Search Results

1. Antibody and T-Cell Responses 6 Months after Coronavirus Disease 2019 Messenger RNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney Transplant

Catalog

Books, media, physical & digital resources

3. Immunogenicity of mRNA-1273 COVID vaccine after 6 months surveillance in health care workers; a third dose is necessary

4. Enhanced Vaccine Effectiveness during the Delta Phase of the COVID-19 Pandemic in the Medicare Population Supports a Multilayered Prevention Approach

5. Long-Term Antibody Response against SARS-CoV-2 in Health Care Workers: Effectiveness of Homologous and Heterologous Regimens and their Relation to Systemic Vaccine-Associated Symptoms

6. Analyses of reported severe adverse events after immunization with SARS-CoV-2 vaccines in the United States: One year on

7. Myocarditis following COVID‐19 mRNA (mRNA‐1273) vaccination

8. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan

9. New-onset chilblains in close temporal association to mRNA-1273 vaccination

10. De-Novo Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Following the mRNA-1273 (Moderna) Vaccine for COVID-19

11. Side Effects of mRNA-Based COVID-19 Vaccines among Young Adults (18–30 Years Old): An Independent Post-Marketing Study

12. Study of humoral and cellular immunity in vaccinated with mRNA-1273

13. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers

14. Six-month interim analysis of ongoing immunogenicity surveillance of the mRNA-1273 vaccine in healthcare workers: A third dose is expected

15. Effectiveness of COVID-19 vaccines

16. Axonal-Variant Guillian-Barre Syndrome Temporally Associated With mRNA-Based Moderna SARS-CoV-2 Vaccine

17. Side Effects of mRNA-Based and Viral Vector-Based COVID-19 Vaccines among German Healthcare Workers

18. Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report

19. Waning antibodies in SARS-CoV-2 naïve vaccinees: Results of a three-month interim analysis of ongoing immunogenicity and efficacy surveillance of the mRNA-1273 vaccine in healthcare workers

20. Asymptomatic SARS-CoV-2 Infection Following First Dose mRNA-1273 COVID-19 Vaccine in a Veterans Affairs Long Term Care Facility

21. Characteristics and outcomes of adverse events after COVID-19 vaccination

22. A Comprehensive Literature Review on the Clinical Presentation, and Management of the Pandemic Coronavirus Disease 2019 (COVID-19)

23. HLA Class II Polymorphism and Humoral Immunity Induced by the SARS-CoV-2 mRNA-1273 Vaccine